Novartis net income 2025| ��ƽ��

Novartis AG's net income from 2007 to 2025 (in billion U.S. dollars)

Characteristic	Net income in billion U.S. dollars
2025	13.97
2024	11.9
2023**	14.9
2022	7
2021	24
2020	8.1
2019*	11.7
2018	12.6
2017	7.7
2016	6.7
2015	17.8
2014	10.3
2013	9.3
2012	9.4
2011	9.1
2010	10
2009	8.5
2008	8.2
2007	6.5

Download

Source

Show detailed source information?

Already a member?

Source

Release date

February 2026

More information

Region

Worldwide

Survey time period

2007 to 2025

Supplementary notes

This statistic was assembled from several editions of Novartis' annual report.
* During this year, the eye care division Alcon was spun off and became an own company.
** During this year, the generics division Sandoz was spun off and became an own company.

Citation formats

Novartis AG, one of the world’s top pharmaceutical companies, reported a high net income of nearly 14 billion U.S. dollars in 2025. However, in 2021, the net income was even higher, at a record high of 24 billion dollars.

Novartis revenue and expenses

Being a Swiss-based company, Novartis generated around one-third of its revenue, namely 16 billion U.S. dollars, in Europe in 2025. With approximately 23 billion U.S. dollars, the United States was the company's most important market in that year. Novartis AG made 37 billion U.S. dollars from its branded pharmaceuticals ("Promoted brands") segment that year, the company’s largest segment.

Novartis spun off its generic drugs division, Sandoz, in mid-2023, while eye care division Alcon was spun off in late April 2019. The company spends most of its resources on SG&A (selling, general, and administration): expenses for this category reached around 12.6 billion U.S. dollars in 2024. Research and development expenditures amounted to some 10 billion U.S. dollars in the same year.